Insights & news

Mental Health Europe Presents Study on European Sunshine and Transparency Rules in Healthcare

  • 23/01/2019
  • Articles

Mental Health Europe (“MHE”), a European non-governmental network organisation active in developing mental health policies, presented on 23 January 2019 its study on transparency rules in European healthcare (“Shedding light on transparent cooperation in healthcare. The way forward for sunshine and transparency laws across Europe” – the “Study”, copy attached).
 
MHE is of the opinion that there is a lack of transparency about the relationship between what it refers to as the “health industry” (essentially suppliers of medicines and pharmaceuticals) and healthcare professionals (“HCPs”), healthcare organisations (“HCOs”) and patient organisations (“POs”). According to MHE, this is a particular problem in the mental health sector and has created an excessive reliance on medication as the prime form of treatment of mental conditions.
 
This has prompted MHE to carry out the Study and make a legal analysis of interactions between the life science industries on the one hand and HCPs and HCOs on the other. The scope of the Study is larger than that of similar earlier initiatives (there was, for example, the mapping exercise carried out in 2017 by a team of researchers from academia and a non-governmental organisation – see, Van Bael & Bellis Life Sciences Newsflash of 22 March 2018). This is because the Study covers more countries, including countries outside the European Union such as Norway and Russia, and also addresses more than transparency rules (which require the publication of transfers of value) to discuss related anti-corruption and conflict-of-interest legislation.
 
The countries under review in the Study present a patchwork of mandatory rules and self-regulation with varying scopes of application. This finding has caused MHE to make the following policy recommendations: 

  • to create minimum standards for the harmonisation of transparency reporting at the European level;
  • to establish a comprehensive and binding set of rules governing the disclosure of transfers of value. In the European Union these rules should take the form of a Directive;
  • to raise awareness of conflicts of interest in both medical education and medical practice and establish rules to manage such conflicts;
  • to broaden scope for independent medical education, including continuing medical education;
  • to expand independent funding for “unbiased” research;
  • to make users of mental health services more attuned to conflicts of interest.

 

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 25/04/2019
    • Articles

    Spanish Competition Authority Raids Pharmaceutical Firm over Suspicions of Abusive Market Behaviour in Relation to Autoimmune Medicine

    The Comisión Nacional de Los Mercados y La Competencia, the Spanish competition authority (“CNMC”), announced today that, earlier this week, it carried out a dawn raid at the premises of an unidentified pharmaceutical firm (see, attached press release). The targeted firm is thought to have abused its dominant position in one or more markets involving the treatment of various unspecified autoimmune diseases. The CNMC suspects that the firm pursued an exclusionary commercial strategy in its dealings with health services (“Servicios de Salud”) and hospitals. The CNMC points out that the medicine at issue went off-patent and that any attempt to corner a market that is supposed to be free following the expiry of relevant patents amounts to a very serious infringement of the competition rules.

    Read more
    • 23/04/2019
    • Articles

    European Parliament Approves Manufacturing Waiver and Reduces Scope of SPC-Based Patent Rights in Medicines

    On 17 April 2019, the European Parliament (“EP”) approved a modification to Regulation No. 469/2009 which governs the supplementary protection certificate (“SPC”) for medicinal products. The modification creates a “manufacturing waiver” that encroaches on the operation of the SPC which, broadly, extends the patent protection afforded to active substances of medicines. The modification will allow EU-based companies to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, for the double purpose of either exporting to a non-EU market where protection has expired or never existed, or stockpiling the medicine during the final 6 months of SPC protection ahead of entry on the EU market once the SPC has lapsed. The “stockpiling” exception goes beyond the proposal which the European Commission initially tabled in May 2018 (see, Van Bael & Bellis Life Sciences Newsflash of 28 May 2018) and did not form part of the text which the Member States determined as their negotiating position in January 2019 (see, Van Bael & Bellis Life Sciences Newsflash of 21 January 2019). Still, the Council of the European Union is now expected to endorse the text adopted by the EP following a political agreement reached among the EU institutions in February 2019. Once published in the Official Journal of the EU, the modification to Regulation No. 469/2009 will enter into force 20 days later and will become directly applicable in all EU Member States. However, the full effects of the SPC waiver will only kick in 3 years after the date of that entry into force, currently expected to be around 1 July 2022. The creation of a manufacturing waiver is regarded as a major victory for the generic and biosimilar industries. Conversely, EFPIA, the European association of innovative pharmaceutical companies, has labelled the move as a “negative signal to the world that Europe is devaluing its intellectual property framework”. EFPIA therefore hopes that the next European Commission, which will take office following the European elections to be held between 23 and 26 May 2019, will “redress the balance, supporting research, development and innovation more broadly” (EFPIA press release of 17 April 2019).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *